Epidermolysis Bullosa Market, by Product Type (Antibiotics, Analgesics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023

Code : CMI2214

Pages :154

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Epidermolysis Bullosa Market Drivers

Increasing clinical trials for the treatment of epidermolysis bullosa is expected to propel the market growth over the forecast period.

For instance, on July 25, 2022, InMed Pharmaceuticals, Inc., which is involved in the research, development, manufacturing, and commercialization of rare cannabinoids INM-755 cannabinol cream for epidermolysis bullosa, provided an update that adolescent patients can participate in the clinical trial.

Moreover, on February 22, 2019, Phoenix Tissue Repair, Inc., a biotechnology company focused on developing a disease-modifying treatment for Dystrophic Epidermolysis Bullosa (DEB), announced that the first patient had been dosed in phase 1/2, first-in-human trial of PTR-01, a protein replacement therapy for recessive DEB.

Global Epidermolysis Bullosa Market Restraint

The high treatment cost of epidermolysis bullosa is expected to hinder the market growth over the forecast period.

For instance, according to the data published in the National Center for Biotechnology Information on September 8, 2020, the average monthly bandage cost epidermolysis bullosa range from US$ 262 to > US$ 2,000.